Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Theralase Announces Warrant Extension
View:
Post by Jaro1977 on Sep 30, 2020 4:34pm

Theralase Announces Warrant Extension

Theralase Announces Warrant Extension @accesswire/theralase-announces-warrant-extension-e9f1b
Comment by enriquesuave on Sep 30, 2020 4:37pm
I guessed right this week. Like I said that means No dilution like some were calling.  It's obvious they have enough cash to get us thru to next data point and or other significant news, at which point extra cash will come from excercised of 30 and 50 cent warrants and no need for further dilution. Should have enough cash for all of PH2 and 1 or 2 PH1 trials. All IMo 
Comment by StevenBirch on Sep 30, 2020 7:37pm
That was a good call.
Comment by anabelsi on Oct 01, 2020 7:57am
Your prediction was on point, thanks Enriquesuave.
Comment by Hankerchief on Oct 01, 2020 9:06am
Wouldn't the share price have to be over 30 and 50 cents in order to stimulate exercising the warrants?  Who would exercise them at 15 cents?
Comment by enriquesuave on Oct 01, 2020 9:21am
Yes of course, they have to be over the excercise price.  This to me means that they expect SP to be higher and to get them excercised eventually without the need to do another raise at 25% discount to SP and another set of warrants.  All IMO. If we hit Mackie SP target of 70-90 cents, then they should get excercised and bring in over $10 Million and no need for another round of dilution ...more  
Comment by anabelsi on Oct 01, 2020 9:22am
Management probably expects the stock price to recover once more data comes out of the study - that would be my guess, or else they would not have extended the warrants.
Comment by CAinPlap on Oct 01, 2020 11:00am
I'd like to get excited about my .50 warrants being extended but then I remember I have more at  .30 to get to first. Would love to fast forward 6 months to see where things are at by then.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250